---
title: "Morning Trend | Giant Biogene's Bullish Confidence Wavers, Key Support at Risk?"
description: "On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan level without success. Throughout the day, funds contin"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273815223.md"
published_at: "2026-01-28T01:00:00.000Z"
---

# Morning Trend | Giant Biogene's Bullish Confidence Wavers, Key Support at Risk?

> On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan level without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating a gradual loss of confidence among bulls, and the main positions began to loosen. The biotechnology sector has shown continued weakness over the past week due to discrepancies in local policies. Funds in the sector are extremely cautious, lacking a leading company to drive momentum, making it difficult to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, and the valuation support story struggles to attract new followers. The overall industry sentiment is low, with funds only able to switch between localized hotspots, leading to a further contraction in risk appetite. 

Technically, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with the dominance of funds leaning more towards the bears. If there are significant active buy orders in the intraday trading, it may signal a turnaround; otherwise, the weak consolidation is likely to continue. 

In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, patiently waiting for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side

On January 27th, GIANT BIOGENE (2367.HK) experienced weak fluctuations during the trading session, repeatedly testing the support at the 28 yuan level without success. Throughout the day, funds continued to flow out, with a high proportion of trading occurring in the red, indicating a gradual loss of confidence among bulls and a loosening of the main positions.

The biotechnology sector has shown continued weakness over the past week due to discrepancies in local policies. Funds in the sector are extremely cautious, lacking leadership from major companies, and there is a lack of momentum to ignite a bullish atmosphere in the short term. GIANT BIOGENE has not released any significant announcements recently, making it difficult for its valuation support story to attract new followers. The overall industry sentiment is low, and funds can only switch between localized hotspots, with risk appetite further contracting.

Technically, indicators such as MACD, KDJ, and RSI have all weakened, and a clear downward channel has formed on the daily chart. Although there have been occasional attempts by the main players to bottom-fish in the short term, there are no signs of an overall trend reversal, with control of funds leaning more towards the bears. If there are significant active buy orders in the intraday trading, it may signal a turnaround; otherwise, the weak consolidation is likely to continue.

In summary, GIANT BIOGENE is currently in a phase of dissipating bullish confidence. If the key support level of 28 yuan is breached, it may trigger a new round of technical sell-off. It is recommended that investors focus on position control, waiting for unusual fund movements and intraday improvement signals, and avoid blindly betting on a rebound from the left side

### Related Stocks

- [02367.HK - GIANT BIOGENE](https://longbridge.com/en/quote/02367.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Morgan Stanley Sticks to Its Buy Rating for Giant Biogene Holding Co. Ltd. (2367) | Morgan Stanley has maintained a Buy rating for Giant Biogene Holding Co. Ltd. with a price target of HK$42.00, while the | [Link](https://longbridge.com/en/news/270232349.md) |
| Giant Biogene Wins China Approval for World-First Collagen–Hyaluronate Skin Implant | Giant Biogene Holding Co. Ltd. has received approval in China for its Recombinant Type I α1 Subtype Collagen and Sodium  | [Link](https://longbridge.com/en/news/272675579.md) |
| Coffee Prices Push Higher on Technical Short Covering | Coffee Prices Push Higher on Technical Short Covering | [Link](https://longbridge.com/en/news/276253604.md) |
| Berkshire Hathaway Bought New York Times Stock in Q4. Should You Add NYT to Your Portfolio Too? | Berkshire Hathaway Bought New York Times Stock in Q4. Should You Add NYT to Your Portfolio Too? | [Link](https://longbridge.com/en/news/276265837.md) |
| Giant Biogene’s Controlling Shareholder Increases Stake to 54.66% | Giant Biogene Holding Co. Ltd. announced that its controlling shareholder, Juzi Holding Co., Ltd., has increased its sta | [Link](https://longbridge.com/en/news/262877363.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.